NEUROONE MEDICAL TECHNOLOGIES Corp
For the period ended Feb 14, 2025. Filed Jan 21, 2025.
View on SEC.govAbout this filing
What shareholders are asked to vote on at a company's meeting. It is where to find what directors and top executives are paid, and who owns the most shares.
Feb 14, 2025 · Filed Jan 21, 2025
Contents
Cover page
Show cover page
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a)
of the Securities Exchange Act of 1934
(Amendment No. )
| Filed by the Registrant | ☒ |
|---|---|
| Filed by a Party other than the Registrant | ☐ |
Check the appropriate box:
| ☐ | Preliminary Proxy Statement |
|---|---|
| ☐ | Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
| ☒ | Definitive Proxy Statement |
| ☐ | Definitive Additional Materials |
| ☐ | Soliciting Material Under §240.14a-12 |
NeuroOne Medical Technologies Corporation
(Name of Registrant as Specified In Its Charter)
N/A
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check all boxes that apply):
| ☒ | No fee required |
|---|---|
| ☐ | Fee paid previously with preliminary materials |
| ☐ | Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 |
NOTICE OF 2025 ANNUAL
MEETING OF STOCKHOLDERS
| WHEN | February 14, 2025 at 9:00 a.m. local time |
|---|---|
| WHERE | 7599 Anagram Dr., Eden Prairie, MN 55344* |
| PURPOSE OF MEETING AND AGENDA | At the 2025 Annual Meeting, stockholders will vote: 1. to elect the Class II director named in the Proxy Statement to a three-year term; 2. to ratify the appointment of our independent registered public accounting firm for 2025; 3. to approve an amendment to our Certificate of Incorporation to effect a reverse split of our outstanding common stock at a ratio in the range of 1-for-2 to 1-for-15 to be determined at the discretion of our Board of Directors, whereby each outstanding 2 to 15 shares would be combined, converted and changed into 1 share of our common stock, to enable the Company to comply with the Nasdaq Stock Market’s continued listing requirements (the “Reverse Stock Split Proposal”); 4. to approve the NeuroOne Medical Technologies Corporation 2025 Equity Incentive Plan; and 5. to authorize one or more adjournments of the Annual Meeting to solicit additional proxies in the event there are insufficient votes to approve the Reverse Stock Split Proposal described above. |
| WHO CAN VOTE | Stockholders of record at the close of business on January 3, 2025. |
| VOTING | Your vote is very important. Please submit your proxy or voting instructions as soon as possible, whether or not you plan to attend the Annual Meeting. |
| ADMISSION TO THE ANNUAL MEETING | All of our stockholders are invited to attend the Annual Meeting. If you attend, you will need to bring valid, government-issued photo identification. The doors to the meeting room will be closed promptly at the start of the meeting. |
- We currently intend to hold the Annual Meeting in person. However, in the event we determine it is not possible or advisable to hold the Annual Meeting in person, we will publicly announce alternative arrangements for the Annual Meeting as promptly as practicable before the Annual Meeting. Please monitor our website atwww.nmtc1.comfor updated information.
Sincerely,
President and Chief Executive Officer
Eden Prairie, Minnesota
January 21, 2025
PROXY STATEMENT FOR 2025 ANNUAL MEETING OF STOCKHOLDERS
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.